<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05036317</url>
  </required_header>
  <id_info>
    <org_study_id>2021-00078; kt21Donath</org_study_id>
    <nct_id>NCT05036317</nct_id>
  </id_info>
  <brief_title>Empagliflozin for the Treatment of Postprandial Hypoglycemia</brief_title>
  <acronym>EmpHy</acronym>
  <official_title>Empagliflozin for the Treatment of Postprandial Hypoglycemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Basel, Switzerland</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Basel, Switzerland</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This randomized trial is to test whether a treatment with empagliflozin is superior to&#xD;
      placebo in patients with postprandial hypoglycemia after bariatric surgery, that is if it&#xD;
      improves health related quality of life (mentally or physically) or reduces the risk of&#xD;
      hypoglycemic events.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Postprandial hypoglycemia is a debilitating medical complication after bariatric surgery for&#xD;
      which no approved pharmacological treatment exists. The prevalence of hypoglycemia in&#xD;
      bariatric patients ranges from 0.5 % severe episodes up to 56 % and its symptoms range from&#xD;
      asymptomatic to deleterious. This hypoglycemic condition is characterized by a rapid increase&#xD;
      of plasma glucose after carbohydrate ingestion followed by an exaggerated hyperinsulinemic&#xD;
      response. Hypoglycemia itself may lead to increased hunger, carbohydrate ingestion and&#xD;
      following weight regain.&#xD;
&#xD;
      In a placebo-controlled, randomized, double-blind, crossover study, the SGLT2-inhibitor&#xD;
      empagliflozin statistically significantly reduced the number of symptomatic hypoglycemia (2&#xD;
      vs. 7 symptomatic hypoglycemic episodes; p=0.013) compared to placebo after a mixed meal test&#xD;
      in 12 patients after Roux-en-Y gastric bypass. Empagliflozin reduced the postprandial rise in&#xD;
      glycemia and decreased subsequent insulin secretion, underlining the postulated mechanism of&#xD;
      action.&#xD;
&#xD;
      This randomized trial is to test whether a treatment with empagliflozin is superior to&#xD;
      placebo in patients with postprandial hypoglycemia after bariatric surgery, that is if it&#xD;
      improves health related quality of life (mentally or physically) or reduces the risk of&#xD;
      hypoglycemic events.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">January 2022</start_date>
  <completion_date type="Anticipated">December 2023</completion_date>
  <primary_completion_date type="Anticipated">December 2023</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>1:1 randomized, placebo-controlled, parallel-group double-blind superiority trial</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>Both subjects and investigators will be blinded.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Quality of life (mental health; as assessed by the SF-36 mental health component score; MCS)</measure>
    <time_frame>at baseline, at day 29 and at day 60 (+/- 10 days) after baseline</time_frame>
    <description>Change in Quality of life (mental health; as assessed by the SF-36 mental health component. Each item is scored on a 0 to 100 range so that the lowest and highest possible scores are 0 and 100, respectively. Scores represent the percentage of total possible score achieved.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Quality of life (physical health; as assessed by the SF-36 mental physical component score; PCS)</measure>
    <time_frame>at baseline, at day 29 and at day 60 (+/- 10 days) after baseline</time_frame>
    <description>Change in Quality of life (physical health; as assessed by the SF-36 mental physical component score; PCS). Each item is scored on a 0 to 100 range so that the lowest and highest possible scores are 0 and 100, respectively. Scores represent the percentage of total possible score achieved.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Hypoglycemic events defined as glucose values below 3.0 mmol/l</measure>
    <time_frame>at 28 days after randomization</time_frame>
    <description>Hypoglycemic events defined as glucose values below 3.0 mmol/l</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Postprandial Symptoms of hypoglycemia defined as acute onset of typical symptoms according to Edinburgh Hypoglycemia Scale along with a decreasing blood glucose level.</measure>
    <time_frame>at 28 days after randomization</time_frame>
    <description>Postprandial Symptoms of hypoglycemia defined as acute onset of typical symptoms according to Edinburgh Hypoglycemia Scale (7-point Likert scale (1 = not present, 7 = very intense)) along with a decreasing blood glucose level. The postprandial period is defined as 3 hours following meal intake.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hypoglycemia unawareness (measured by modified Clarke Score)</measure>
    <time_frame>at 28 days after randomization</time_frame>
    <description>Hypoglycemia unawareness (measured by modified Clarke Score). The Clarke method comprises eight questions characterizing the participant's exposure to episodes of moderate and severe hypoglycemia. It also examines the glycemic threshold for, and symptomatic responses to, hypoglycemia. A score of four or more implies impaired awareness of hypoglycemia.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fear of hypoglycemia (measured on a scale of 0 to 10)</measure>
    <time_frame>at 28 days after randomization</time_frame>
    <description>Fear of hypoglycemia (measured on a scale of 0 to 10)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time below range (TBR): % of sensor glucose readings and time between 3.0 and 3.8 mmol/L)</measure>
    <time_frame>at 28 days after randomization</time_frame>
    <description>Time below range (TBR): % of sensor glucose readings and time between 3.0 and 3.8 mmol/L)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time in hypoglycemia: % of sensor glucose readings and time below 3.0 mmol/L</measure>
    <time_frame>at 28 days after randomization</time_frame>
    <description>Time in hypoglycemia: % of sensor glucose readings and time below 3.0 mmol/L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pattern of sensor glucose</measure>
    <time_frame>at 28 days after randomization</time_frame>
    <description>Pattern of sensor glucose, defined as the slope of postprandial increase (calculated as the maximal rate of increase observed over 20min in the postprandial period) and decrease (calculated as the maximal rate of decrease over 20min in the postprandial period).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glycemic variability</measure>
    <time_frame>at 28 days after randomization</time_frame>
    <description>Glycemic variability (defined as the coefficient of variation (CV) of sensor glucose)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean amplitude of sensor glucose excursions (MAGE)</measure>
    <time_frame>at 28 days after randomization</time_frame>
    <description>Mean amplitude of sensor glucose excursions (MAGE)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total number of adverse events</measure>
    <time_frame>up to 60 days after randomization</time_frame>
    <description>Total number of adverse events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Serious adverse events</measure>
    <time_frame>up to 60 days after randomization</time_frame>
    <description>Number of Serious adverse events</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">62</enrollment>
  <condition>Postprandial Hypoglycemia</condition>
  <arm_group>
    <arm_group_label>Empagliflozin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Standard dose of empagliflozin (Jardiance®; Boehringer Ingelheim GmbH), i. e. 10 mg. Empagliflozin is an orally available inhibitor of SGLT2 and approved for the treatment of type 2 diabetes mellitus and will be given per os once daily in the morning for 28 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo provided by Boehringer Ingelheim Switzerland. Per os once daily in the morning for 28 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Empagliflozin (Jardiance®;</intervention_name>
    <description>Each tablet contains the active substance of 10 mg empagliflozin as well as the adjuvant lactose-monohydrate and is taken orally once daily in the morning.</description>
    <arm_group_label>Empagliflozin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo Control Intervention</intervention_name>
    <description>Placebo will be provided by Boehringer Ingelheim. It is identical to the interventional product apart from the active compound.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients after bariatric surgery (i.e. sleeve gastrectomy, Roux-en-Y gastric bypass,&#xD;
             omega- loop bypass, biliopancreatic diversion) with documented hypoglycemia, i. e. &lt;&#xD;
             3.0 mmol/l and at least 5 hypoglycemic episodes per week despite dietary modification&#xD;
&#xD;
          -  For women with child-bearing potential, willingness to use contraceptive measures&#xD;
             adequate to prevent pregnancy during the study&#xD;
&#xD;
          -  Informed Consent as documented by signature&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any type of diabetes mellitus according to ADA criteria&#xD;
&#xD;
          -  Intolerance to the study drug&#xD;
&#xD;
          -  Signs of current infection&#xD;
&#xD;
          -  Use of any drug therapy for postbariatric hypoglycemia apart from acarbose (all&#xD;
             remaining drugs have to be discontinued four half-life times before screening phase)&#xD;
&#xD;
          -  Neutropenia (leukocyte count &lt; 1.5 × 109/L or absolute neutrophil count (ANC) &lt; 0.5 ×&#xD;
             109/L)&#xD;
&#xD;
          -  Anemia (hemoglobin &lt; 11 g/dL for males, &lt; 10 g/dL for females)&#xD;
&#xD;
          -  Clinically significant kidney or liver disease (creatinine &gt; 1.5 mg/dL, AST/ALT &gt; 2 ×&#xD;
             ULN, alkaline phosphatase &gt; 2 × ULN, or total bilirubin [tBili] &gt; 1.5 × ULN)&#xD;
&#xD;
          -  Uncontrolled congestive heart failure&#xD;
&#xD;
          -  Uncontrolled malignant disease&#xD;
&#xD;
          -  Currently pregnant or breastfeeding&#xD;
&#xD;
          -  Known or suspected non-compliance, drug or alcohol abuse&#xD;
&#xD;
          -  Meeting the criteria for vulnerability (e.g. participants incapable of judgment or&#xD;
             participants under tutelage)&#xD;
&#xD;
          -  Inability to follow the procedures of the study, e.g. due to language problems,&#xD;
             psychological disorders, dementia, etc.&#xD;
&#xD;
          -  Participation in another clinical trial using investigational drugs in the last 30&#xD;
             days or planned participation in the next 60 days&#xD;
&#xD;
          -  Previous enrolment into the current study,&#xD;
&#xD;
          -  Enrolment of the investigator, his/her family members, employees and other dependent&#xD;
             persons&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marc Y Donath, Prof. Dr. med.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital Basel, Division of Endocrinology, Diabetes and Metabolism</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Marc Y Donath, Prof. Dr. med.</last_name>
    <phone>+41 61 265 25 25</phone>
    <email>marc.donath@usb.ch</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Matthias Hepprich, Dr. med.</last_name>
    <phone>+41 61 328 60 77</phone>
    <email>matthias.hepprich@usb.ch</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Hospital Basel, Division of Endocrinology, Diabetes and Metabolism</name>
      <address>
        <city>Basel</city>
        <zip>4031</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marc Y Donath, Prof. Dr. med.</last_name>
      <phone>+41 61 265 25 25</phone>
      <email>marc.donath@usb.ch</email>
    </contact>
    <contact_backup>
      <last_name>Matthias Hepprich, Dr. med.</last_name>
      <phone>+41 61 328 60 77</phone>
      <email>matthias.hepprich@usb.ch</email>
    </contact_backup>
    <investigator>
      <last_name>Marc Y Donath, Prof. Dr. med.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Matthias Hepprich, Dr. med.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jonathan Mudry</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital Bern and Center for Bariatric Surgery Berne</name>
      <address>
        <city>Bern</city>
        <zip>3011</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lia Bally, Prof. Dr. med.</last_name>
      <email>lia.bally@insel.ch</email>
    </contact>
    <contact_backup>
      <last_name>David Herzig, Dr. med.</last_name>
      <email>david.herzig@extern.insel.ch</email>
    </contact_backup>
    <investigator>
      <last_name>Lia Bally, Prof. Dr. med.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>David Herzig, Dr. med.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Department of Endocrinology Cantonal Hospital Olten</name>
      <address>
        <city>Olten</city>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gottfried Rudofsky, Prof. Dr. med.</last_name>
      <email>gottfried.rudofsky@spital.so.ch</email>
    </contact>
    <investigator>
      <last_name>Gottfried Rudofsky, Prof. Dr. med.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>September 1, 2021</study_first_submitted>
  <study_first_submitted_qc>September 1, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 5, 2021</study_first_posted>
  <last_update_submitted>November 16, 2021</last_update_submitted>
  <last_update_submitted_qc>November 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Empagliflozin</keyword>
  <keyword>bariatric surgery</keyword>
  <keyword>hyperinsulinemic response</keyword>
  <keyword>SGLT2-inhibitor</keyword>
  <keyword>insulin secretion</keyword>
  <keyword>postbariatric hypoglycemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypoglycemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Empagliflozin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

